Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Venous Thromboembolism 3Neoplasms 3Venous Thrombosis 2Thrombosis 2Pancreatic Neoplasms 2Thromboembolism 1Stomach Neoplasms 1Pulmonary Embolism 1Ovarian Neoplasms 1Obesity 1Multiple Myeloma 1Gliosarcoma 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Embolism and Thrombosis 1Embolism 1Duodenal Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Central Nervous System Neoplasms 1Carcinoma, Hepatocellular 1Biliary Tract Neoplasms 1

Interventions

Bevacizumab 233Fluorouracil 219Oxaliplatin 215Irinotecan 215Leucovorin 198Capecitabine 153Cetuximab 145Panitumumab 70Folfox protocol 51regorafenib 43Radiotherapy 38pembrolizumab 37IFL protocol 36HMPL-013 36trifluridine tipiracil drug combination 32Nivolumab 32Drug Therapy 26Neoadjuvant Therapy 24Trifluridine 18Celecoxib 18tislelizumab 17XELOX 17sintilimab 16Trastuzumab 16durvalumab 15atezolizumab 15aflibercept 15Chemotherapy, Adjuvant 15apatinib 14Gemcitabine 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Colorectal Neoplasms × Dalteparin × Clear all
NCT00323011 2014-05-21

FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer

University of Southern California

Phase 2 Terminated
5 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡